|  

PET-CT

In Doctors Hospital, we have PET-CT Biograph mCT de Siemens equipment (Tomography by Emission of Positrons fused with Computerized Axial Tomography) which allows us to detect cancer in its initial stages, as well as the level of alteration of the cellular function and metastasis, and to specify the location of a malignant tumor years before the first symptoms can be evaluated by any other oncological diagnostic method.

 

It is the latest form of non-invasive diagnosis and it shows the metabolic or physiological condition of a patient’s illness (generated by PET) within the anatomical structure (generated by CT). The fusion of images shows us the precise location of tumorous tissue and it allows for the evaluation of the status of the illness in our patients and their response to treatments received.

 

 

AMONG THE ADVANTAGES OFFERED IN THIS SYSTEM ARE FOUND:

• Precise and opportune diagnosis, since the disease is detected before structural changes are produced.

• Evaluation of the extension of the illness.

• Prognosis and identification of tumor relapses and evaluation of the therapeutic response to Chemotherapy and Radiation.

• Non-invasive method that does not produce alterations in the patient’s state.

 

PET-CT Study in Monterrey

PET-CT (Tomography by Emission of Positrons fused with Computerized axial Tomography)

To successfully locate a tumor through PET-CT, or to evaluate the status of a specific illness, it is necessary to use radiopharmaceuticals produced by the Cyclotron Laboratory in Monterrey in our Medical Center, which has GE Mini-trace Cyclotron equipment, the only generator of radioisotopes used in medical diagnosis in northern Mexico, and the same produces the following radiopharmaceuticals in accordance to the corresponding diagnosis:

 

 

Our own Radiopharmacy Laboratory in Monterrey for the production of PET radiopharmaceuticals allows us to make the previously indicated diagnoses, which substantially increases specificity in order to obtain optimum results.

In the same manner, it allows us to have radiopharmaceuticals required for our patients’ medical diagnostic studies. The radiopharmaceutical most used for oncological diagnosis is the 18F-FDG (Fluorodesoxyglucose marked with fluoride-18), and diagnostic results are validated by the FDA (Food and Drug Administration) in cancers of the:

 

  • Lung
  • Head tumors.
  • Breast.
  • Neck.
  • Colon.
  • Kidney
  • Lymphoma.
  • Melanoma.
  • Among others.

Our service is recognized nationally and internationally among the hospitals in Monterrey to be that with greatest growth, with certified specialists and with personnel in our Medical Center who are greatly trusted by our patients and who provide them with warmth and comfort.


Contact

Dr. José Humberto Treviño Ortiz

Department Head

informacion@ocahospital.mx

01 (81) 5515-5000 ext. 3974, 3975, 3976, 3977